THE WOODLANDS, Texas - Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX) has revealed findings from a post hoc analysis of its inTandem3 Phase 3 trial, indicating that sotagliflozin could benefit patients with type 1 diabetes and chronic kidney disease (CKD). The analysis, presented last week at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy, showed that sotagliflozin improved glycemic control, reduced body weight, and lowered systolic blood pressure without compromising safety.
The trial involved a subgroup of 228 participants with type 1 diabetes and CKD, who were given sotagliflozin 400 mg daily alongside insulin therapy. Results were compared to a placebo group and demonstrated similar reductions in A1C levels, body weight, and systolic blood pressure. Additionally, the risks of severe hypoglycemia were comparable between the CKD subgroup and the total cohort.
David Z.I. Cherney, M.D., Ph.D., from the University of Toronto and a contributing author of the study, emphasized the significance of these findings for patients with type 1 diabetes and CKD. Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer, expressed optimism about sotagliflozin's potential as a new treatment option for this patient group.
Lexicon Pharmaceuticals focuses on the development of medicines targeting proteins identified through its Genome5000™ program. The company has successfully brought multiple drugs to market and has a diverse pipeline of drug candidates in various stages of development.
The company plans to resubmit its New Drug Application for sotagliflozin as an adjunct to insulin therapy for people with type 1 diabetes and CKD, based on the strength of the trial data. This analysis is part of Lexicon's ongoing research and development efforts in diabetes and metabolism treatments.
The information provided is based on a press release statement from Lexicon Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.